Last edition
News about "neurological disorders"
Akums Launches DCGI-Approved Triple-Action Therapy for Diabetic Neuropathic Pain
Akums Drugs & Pharmaceuticals has introduced a DCGI-approved triple-action capsule that combines pregabalin, methylcobalamin and delayed-release duloxetine to offer comprehensive management of diabetic peripheral neuropathic pain while supporting nerve regeneration.
Neurological Disorders | 01/07/2026 | By News Bureau | 110
Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies
Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.
Neurological Disorders | 26/06/2026 | By News Bureau
Teva Completes Acquisition of Emalex Biosciences
Teva has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline. The deal supports Teva’s Pivot to Growth strategy.
Neurological Disorders | 12/06/2026 | By News Bureau | 140
Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal
The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.
Neurological Disorders | 07/04/2026 | By News Bureau | 106
Oragenics, Sterling Pharma Solutions Ink Manufacturing Deal for Concussion Drug
Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.
Neurological Disorders | 18/07/2025 | By Dineshwori | 277
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy